Nasus Pharma (NSRX) Payables (2024 - 2025)
Nasus Pharma (NSRX) reported Payables of $829000.0 for Q4 2025, down 16.01% on a YoY basis from $987000.0 in Q4 2024, and down 16.01% quarter-over-quarter from $987000.0 in Q4 2024.
Nasus Pharma (NSRX) Payables (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Payables for 2 years, with the latest figure at $829000.0 in Q4 2025.
- For the quarter ending Q4 2025, Payables fell 16.01% year-over-year to $829000.0; the trailing twelve-month figure through Dec 2025 stood at $829000.0 (down 16.01% YoY), and the FY2025 full-year result was $829000.0, down 16.01% from the prior year.
- Payables for Q4 2025 stood at $829000.0, down from $987000.0 in the prior quarter.
- The five-year high for Payables was $987000.0 in Q4 2024, with the low at $829000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -26.13 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 27.92 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 6.01 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | 829,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 829,000.00 |
| Dec 31, 2024 | 987,000.00 |